RBC Reiterates Outperform Rating on Ariad (ARIA)
Tweet Send to a Friend
RBC Capital today maintained an Outperform rating on Ariad Pharmaceuticals (NASDAQ: ARIA) with a price target of $28.00. Analyst Michael ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE